Is DCTH a buy? - Seeking Alpha

Quote & Headlines Market Currents StockTalk

Today 5d 1m 3m 1y 5y 10y

52wk high:

52wk low:

EPS:

PE:

Div Rate:

Yield:

Market Cap:

Volume:

2,579 people get DCTH articles and Market Currents by email alert.

Get email alerts on DCTH »

HEADLINES:

Delcath Systems Management Discusses Q1 2013 Results - Earnings Call Transcript
Wed, May 8
Looking For Opportunity - 5 Biotechs That Crashed
Craig Keolanui • Mon, May 6 • 13 Comments
The ODAC Postmortem: Lessons Learned Part 2, Delcath Systems
PropThink • Mon, May 6 • 5 Comments
Delcath Systems: Too Many Red Flags To Hold Through May 2nd ODAC
Linch Financial • Mon, Apr 29 • 49 Comments
Delcath: A Cancer Treatment Biotech With Good Short And Long-Term Potential
Healthcare Specialist • Sun, Apr 21 • 23 Comments
BSD Medical News To Create A Spark
Amy Baldwin • Thu, Apr 11 • 14 Comments
2 Biotechs With 40%+ Moves Coming
Equity Options Guru • Mon, Apr 8 • 11 Comments
3 Healthcare Stocks Waiting For The FDA's Approval
Emerging Equities • Fri, Apr 5
2 Speculative Small Cap Drug Stocks Pending Key FDA Approvals
Bret Jensen • Wed, Mar 27 • 28 Comments
2 Cancer Biotechs With Upcoming FDA Approval Decisions In 2013
David Zanoni • Fri, Mar 22 • 19 Comments
Bio Run-Ups: What To Expect In The Next Few Months
Alexander Maxwell • Fri, Mar 22 • 33 Comments
Delcath Poised For Run-Up Into FDA Advisory Panel Meeting
Mike Havrilla • Sun, Mar 17 • 7 Comments
Delcath Systems Management Discusses Q4 2012 Results - Earnings Call Transcript
Wed, Mar 13
3 Med Device Stocks Looking Very Attractive
Brian L. Wilson • Tue, Mar 12 • 5 Comments
Delcath Drifts 30% Higher On PDUFA Anticipation
Brian L. Wilson • Mon, Mar 11 • 19 Comments
4 Biotech Stocks Looking To Heat Up In Time For Summer
Craig Keolanui • Sun, Mar 10 • 4 Comments
Delcath Systems: Bullish On Melblez FDA Panel Vote And Subsequent Approval
PropThink • Fri, Mar 8 • 6 Comments
Delcath Systems: 'Improving The Bicycle' In Chemotherapy
Linch Financial • Wed, Feb 27 • 33 Comments
The Business Of Cancer
Marc Lichtenfeld • Wed, Feb 6 • 3 Comments
Cancer Radiation Stocks To Consider: Delcath, Spectrum And IsoRay
BuySellShort • Tue, Feb 5 • 3 Comments

To learn more about Seeking Alpha Pro, click here.

The ODAC Postmortem: Lessons Learned Part 2, Delcath Systems
PropThink • Mon, May 6 • 5 Comments
Delcath Systems: Too Many Red Flags To Hold Through May 2nd ODAC
Linch Financial • Mon, Apr 29 • 49 Comments
Delcath: A Cancer Treatment Biotech With Good Short And Long-Term Potential
Healthcare Specialist • Sun, Apr 21 • 23 Comments
Delcath Poised For Run-Up Into FDA Advisory Panel Meeting
Mike Havrilla • Sun, Mar 17 • 7 Comments
Delcath Drifts 30% Higher On PDUFA Anticipation
Brian L. Wilson • Mon, Mar 11 • 19 Comments
Delcath Systems: Bullish On Melblez FDA Panel Vote And Subsequent Approval
PropThink • Fri, Mar 8 • 6 Comments
Delcath Systems: 'Improving The Bicycle' In Chemotherapy
Linch Financial • Wed, Feb 27 • 33 Comments
Is Delcath The Post-Celsion Play On Liver Cancer?
Brian L. Wilson • Mon, Feb 4 • 19 Comments
3 Reasons Delcath Systems Appears Undervalued
Justin Kuepper • Wed, Jan 23 • 11 Comments
Delcath Systems: A Frustrating Stock With Quite A Bit Of Value Potential
Brian L. Wilson • Wed, Oct 17, 2012 • 7 Comments
Interview: Delcath's CEO Provides Details About The Resubmission Of The FDA's New Drug Application For CHEMOSAT
Ben Yoffe • Wed, Oct 3, 2012 • 7 Comments
Delcath Systems: An Exclusive Interview With ROTH Capital Senior Analyst
Ben Yoffe • Fri, Sep 28, 2012 • 4 Comments
Delcath Is About To Change The Way We Treat Liver Cancer
Icarus Falling • Wed, Aug 8, 2012 • 22 Comments
Novel Cancer Treatment Gains Acceptance
Steven Bulwa • Wed, Apr 11, 2012 • 8 Comments
Delcath System's Two Chances of Legitimacy in 2011
Chemistfrog • Thu, Feb 17, 2011 • 21 Comments
Bullish Sentiment Continues for Delcath
M. E. Garza • Tue, Jan 4, 2011
Delcath Systems Is Still a Great Buy: Thoughts on Q3, So Far
Tim Shaw • Wed, Nov 3, 2010 • 4 Comments
Buyout or No, Delcath Offers a Valuable Investment Opportunity
Rockford Coscia • Wed, Nov 3, 2010 • 8 Comments
Delcath Systems: A Great Buy at These Prices
Tim Shaw • Tue, Aug 31, 2010 • 13 Comments
Delcath Systems' Cancer Study Results Reveal Huge Potential
Intelligent Investor Junior • Tue, Jun 8, 2010 • 17 Comments

Looking For Opportunity - 5 Biotechs That Crashed
Craig Keolanui • Mon, May 6 • 13 Comments
BSD Medical News To Create A Spark
Amy Baldwin • Thu, Apr 11 • 14 Comments
2 Biotechs With 40%+ Moves Coming
Equity Options Guru • Mon, Apr 8 • 11 Comments
3 Healthcare Stocks Waiting For The FDA's Approval
Emerging Equities • Fri, Apr 5
2 Speculative Small Cap Drug Stocks Pending Key FDA Approvals
Bret Jensen • Wed, Mar 27 • 28 Comments
2 Cancer Biotechs With Upcoming FDA Approval Decisions In 2013
David Zanoni • Fri, Mar 22 • 19 Comments
Bio Run-Ups: What To Expect In The Next Few Months
Alexander Maxwell • Fri, Mar 22 • 33 Comments
3 Med Device Stocks Looking Very Attractive
Brian L. Wilson • Tue, Mar 12 • 5 Comments
4 Biotech Stocks Looking To Heat Up In Time For Summer
Craig Keolanui • Sun, Mar 10 • 4 Comments
The Business Of Cancer
Marc Lichtenfeld • Wed, Feb 6 • 3 Comments
Cancer Radiation Stocks To Consider: Delcath, Spectrum And IsoRay
BuySellShort • Tue, Feb 5 • 3 Comments
Q3 2012 Pharma Company Updates Indicate Upcoming Catalysts
Chemistfrog • Tue, Nov 27, 2012 • 9 Comments
Biotech Weekend Recap: Bears, Bears Everywhere
Brian L. Wilson • Mon, Oct 22, 2012 • 15 Comments
Cancer Treatment Need Is The Mother Of Novel Solutions
Chemistfrog • Tue, Sep 11, 2012 • 9 Comments
Biotechnology And Drug Stocks Up For FDA Approval In August
StockPandit • Mon, Jul 2, 2012 • 4 Comments
Notable Micro Cap Insider Buys Last Week
Gutone • Sat, Jun 9, 2012 • 4 Comments
Hyper-Novel Investments For Targeting Cancer
A John Hodge • Wed, May 30, 2012 • 3 Comments
Targeted Chemotherapy: The Perfect Balance Between Safety And Efficacy?
Chemistfrog • Mon, May 7, 2012 • 6 Comments
Analyzing Friday's Noteworthy Insider Buys And Sells
GuruFundPicks • Sun, Jan 8, 2012 • 4 Comments
7 Healthcare Stocks With January Catalysts
Spencer Knight • Tue, Jan 3, 2012 • 2 Comments

Delcath Systems Management Discusses Q1 2013 Results - Earnings Call Transcript
Wed, May 8
Delcath Systems Management Discusses Q4 2012 Results - Earnings Call Transcript
Wed, Mar 13
Delcath Systems' CEO Presents at Lazard Capital Markets 9th Annual Healthcare Conference (Transcript)
Tue, Nov 13, 2012
Delcath Systems Management Discusses Q3 2012 Results - Earnings Call Transcript
Wed, Nov 7, 2012 • 1 Comment
Delcath Systems 's CEO Discusses Q2 2012 Results - Earnings Call Transcript
Tue, Aug 7, 2012

Movers & Shakers: Friday’s movers: Regeneron, LinkedIn

at MarketWatch.com (May 3, 2013)
Delcath Submits New Drug Application For Proprietary Chemosaturation System To The U.S. Food And Drug Administration

PR Newswire (Aug 15, 2012)
Delcath To Present At Upcoming Investor Conferences

PR Newswire (Aug 8, 2012)
Delcath Reports Second Quarter 2012 Financial Results And Highlights Recent Accomplishments

PR Newswire (Aug 7, 2012)
Delcath To Conduct Second Quarter 2012 Results Conference Call

PR Newswire (Jul 17, 2012)
Delcath To Present At JMP Securities Healthcare Conference On July 12

PR Newswire (Jul 9, 2012)
Delcath Announced Changes To Board Of Directors

PR Newswire (Jul 9, 2012)
Delcath To Offer Second Generation Hemofiltration Cartridge In U.S. Expanded Access Program

PR Newswire (Jun 18, 2012)
Post-Hoc Analysis Of Delcath's Phase 3 Trial Presented At ASCO

PR Newswire (Jun 5, 2012)
Delcath Announces Exercise of Underwriters' Over-Allotment Option and Closing of $23 Million Public Offering of Common Stock and Warrants

PR Newswire (May 31, 2012)
Delcath To Host Analyst Meeeting

PR Newswire (May 30, 2012)
Movers & Shakers: Friday’s top gaining and declining stocks

at MarketWatch.com (May 25, 2012)
Delcath Prices $20 Million Public Offering of Common Stock and Warrants

PR Newswire (May 25, 2012)
Delcath Announces Proposed Public Offering Of Common Stock And Warrants

PR Newswire (May 24, 2012)
Delcath to Webcast Management's Presentation at Annual Meeting of Stockholders

PR Newswire (May 21, 2012)
Delcath Highlights First Quarter 2012 And Recent Accomplishments

PR Newswire (May 8, 2012)
Delcath To Report Fiscal 2012 First Quarter Results And Conduct Conference Call

PR Newswire (May 1, 2012)
Low Side Effects Seen in Treatment With Delcath's Second Generation Hemofiltration Cartridge

PR Newswire (Apr 26, 2012)
Delcath Systems, Inc. Secures $20 Million Credit Facility

PR Newswire (Apr 23, 2012)
Delcath Announces First Patient Treatment Using Second Generation Hemofiltration Cartridge

PR Newswire (Apr 13, 2012)

DCTH vs. ETF Alternatives

Company Description

We are a development stage company that has developed an innovative system designed to administer high dose chemotherapy and other therapeutic agents to diseased organs or regions of the body. Since our inception we have focused our efforts on the development of a single product, the Delcath... More

Sector: Healthcare

Industry: Drug Delivery & Accessories

Country: United States

All
| Earnings
| Dividends
| M&A
| On the move

Wednesday, May 8, 5:22 PM More on Delcath Systems (DCTH): Q1 comes up short on a per share basis but beats on the revenue side. Most of the revenue gain was related to the recognition of previously deferred revenue as a result of satisfying certain requirements of the its Research and Distribution agreement with Chi-Fu Trading in Taiwan, while the remainder was from product sales. SG&A and R&D expenses both declined, primarily due to a significant reduction in expenses related to the its New Drug Application submission to the FDA. Shares -4% AH. Comment! [Earnings, On the Move]
Wednesday, May 8, 5:21 PM Delcath (DCTH): Q1 EPS loss of -$0.15 misses by $0.02. Revenue of $400K (+42% Y/Y) beats by $120K. (PR). Shares -4% AH. Comment! [Healthcare, Earnings, Breaking News, On the Move]
Friday, May 3, 9:54 AM Delcath Systems (DCTH -48.9%) collapses after the FDA votes unanimously against the company's Melblez Kit, as the risks purportedly outweigh the benefits. The shares were halted Thursday pending the announcement. DCTH is the second casualty of this week's Oncologic Drugs Advisory Board, as Aveo Pharmaceuticals (AVEO +1.5%) received a similarly disappointing panel vote on Tivozanib. (Background: I, II) Comment! [Healthcare, On the Move]
Thursday, May 2, 1:34 PM Shares of Delcath Systems (DCTH +4.7%) are halted as the FDA's Oncologic Drugs Advisory Committee meets to discuss its new drug application for marketing approval of its its Melblez Kit for Injection, which is used to treat patients with unresectable ocular melanoma metastatic to the liver. The stock had been hit hard last week after the FDA expressed concern over the treatment's high death rate. 2 Comments [Healthcare, On the Move]
Tuesday, April 30, 12:46 PM Midday top 10 gainers: TTHI +45%. PTIE +26%. DRRX +26%. MTOR +23%. MGAM +20%. OIS +16%. GIB +14%. HGSH +15%. ARWR +13%. TXRH +13%.
Midday top 10 losers: DCTH -44%. AVEO -26%. NUAN -18%. AOSL -18%. PBI -16%. AEIS -13%. MSTR -10%. ANV -10%. ELTK -10%. SYN -10%. Comment! [On the Move]
Tuesday, April 30, 9:44 AM Delcath Systems (DCTH -12.9%) opens sharply lower after the FDA posts a briefing document for the Oncologic Drugs Advisory Committee's discussion of DCTH's ocular melanoma injection Melblez on its website. 2 Comments [Healthcare, On the Move]
Tuesday, April 30, 9:10 AM Premarket gainers: HPY +10%. HTWR +9%. ANAD +9%. AVP +8%. UBS +7%. BBY +6%.
Losers: DCTH -20%. AVEO -16%. NUAN -15%. PBI -10%. MTG -8%. CNH -6%. RVBD -6%. QGEN -5%. Comment! [On the Move]
Tuesday, April 9, 1:08 PM Delcath Systems (DCTH -8.8%) takes a hit today after announcing that it is expanding workforce reductions in an effort to reduce costs. It now says it plans to cut up to 21% of its workforce, with allowance for with sufficient resources for at least the next 12 months as the Company pursues three key objectives: FDA approval for its MelblezTM Kit, European commercialization of CHEMOSAT Hepatic Delivery System for melphalan hydrochloride, and ongoing clinical development focused on label expansion. Comment! [Healthcare, On the Move]
Monday, April 8, 9:10 AM Premarket gainers: LUFK +38%. BSDM +34%. BCRX +18%. UNXL +15%. GOL +10%. TSL +7%.
Losers: OMPI -6%. DCTH -5%. Comment! [On the Move]
Monday, April 8, 8:49 AM Delcath Systems (DCTH) -5.1% after the FDA extends by three months the period for deciding whether to approve the company's Melblez Injection for use with the firm's Hepatic Delivery System, its drug/device combination product for the treatment of patients with unresectable ocular melanoma metastatic to the liver. The FDA is now due to give a decision in September. (PR) 1 Comment [On the Move, Healthcare]
Thursday, March 14, 9:15 AM Premarket gainers: MW +15%. EBIX +14%. ARWR +8%. BLDP +6%. FTE +6%.
Losers: ANAD -8%. NBG -7%. DCTH -7%. ETFC -7%. VRA -6%. Comment! [On the Move]
Wednesday, March 13, 7:31 PM More on Delcath Systems (DCTH): Q4 beats on a per share basis but comes up short on the revenue side. SG&A expenses were higher, primarily due to increased EU commercialization expenses, but were largely offset by lower R&D expenses, which reflected lower consulting expenses following the submission FDA applications for its chemosaturation system. The company also filed a shelf registration to sell up to $50M in stock. Shares -8.3% AH. 2 Comments [Healthcare, Earnings, On the Move]
Wednesday, March 13, 4:21 PM Delcath Systems (DCTH): Q4 EPS of -$0.14. Revenue of $200K misses by $130K. (PR) 5 Comments [Earnings, Breaking News, Healthcare]
Monday, March 4, 2:33 PM Delcath (DCTH +10.4%) resumes its trek higher again today, adding to its run over the past few sessions. Late last week, the company said the FDA's Oncologic Drugs Advisory Committee will review a new drug application for it's Melblez KitTM for Injection drug/device combination for use with the Delcath Hepatic Delivery System. Comment! [Healthcare, On the Move]
Wednesday, February 27, 8:09 AM An FDA advisory panel will review on May 2 Delcath's (DCTH) application for using its Hepatic Delivery System and melphalan hydrochloride to treat patients with unresectable ocular melanoma that is metastatic to the liver. Shares are +2.7% but down from earlier highs. (PR) 3 Comments [Healthcare, On the Move]
Tuesday, February 26, 9:10 AM Premarket gainers: CWH +28%. ALC +22%. ARWR +17%. AXTI +8%. SPRD +7%. AUXL +6%. DCTH +5%.
Losers: TWI -10%. VVUS -7%. VSI -7%. EEQ -5%. 1 Comment [On the Move]

whitehead1
No one has anything to say about $DCTH now?
May 16, 10:50 PM
Reply

• !Report Abuse
View all 0 replies
Add a reply...

140 characters

whitehead1
$DCTH: FDA stll reviewing today? does anyone know?
May 2, 10:28 AM
Reply

• !Report Abuse
View all 0 replies
Add a reply...

140 characters

Tony Kau
Hit the May 2/3 $DCTH call credit spread this morning for 0.13, 95% chance of profit
Apr 24, 1:20 PM
Reply

• !Report Abuse
View all 0 replies
Add a reply...

140 characters

Red Acre Investments
Binary Event Watch April 2013 - Part II http://bit.ly/114CVMl ... $RPTP $AVEO $DCTH $VVUS $SRPT $PFE $DRRX $PTIE $TTNP $XNPT $EXAS
Apr 12, 12:25 PM
Reply

• !Report Abuse
View all 0 replies
Add a reply...

140 characters

Red Acre Investments
April binary event watch pt2 $PFE $RPTP $TTNP $AVEO $DCTH $PFE $SRPT $VVUS $AGN $DRRX $PTIE $XNPT $EXAS get it free: http://bit.ly/10SbDco
Apr 11, 7:03 PM
Reply

• !Report Abuse
View all 0 replies
Add a reply...

140 characters

Jason F
$DCTH PDUFA Delay Offers New Trade Opportunity http://bit.ly/16J7Q3j (chart analysis)
Apr 8, 7:24 PM
Reply

• !Report Abuse
View all 0 replies
Add a reply...

140 characters

Jason F
$DCTH Technical Update after Friday's impressive move. http://bit.ly/10jGqgQ
Mar 30, 2:16 PM
Reply

• !Report Abuse
View all 0 replies
Add a reply...

140 characters

Jason F
$DCTH Technical Chart Observations http://stks.co/eOdq
Mar 26, 9:30 PM
Reply

• !Report Abuse
View all 0 replies
Add a reply...

140 characters

Jason F
Why $DCTH is poised to bounce (1 Hour Time Frame Chart analysis) http://bit.ly/11hAAgD
Mar 20, 8:36 PM
Reply

• !Report Abuse
View all 0 replies
Add a reply...

140 characters

baole1985
$DCTH drop 10% today? what going on before earning report?
Mar 13, 4:23 AM
Reply

• !Report Abuse
View all 0 replies
Add a reply...

140 characters

LATEST REPLIES

dantriot
Does somebody know what/when are the next milestones for $DCTH ? i am long on DCTH and waiting for some volatility (maybe sell/buy options)
Mar 6, 8:25 AM
Reply (4)

• !Report Abuse
View all 4 replies
terrorbytefx: $DCTH - Don't they have something coming up in May, the 2nd I believe?
Mar 20, 12:00 PM
• !Report Abuse
terrorbytefx: $DCTH - Don't they have something coming up in May, the 2nd I believe?
Mar 20, 12:00 PM
• !Report Abuse
Add a reply...

140 characters

LEIGHDIST
does anyone know why the move today???? $DCTH
Jan 31, 9:40 AM
Reply (7)

• !Report Abuse
View all 7 replies
LEIGHDIST: let's cross our fingers, taking a loss on amrn i don't need another one, do you still have amrn
Feb 1, 9:07 AM
• !Report Abuse
nsahbti: Of course but I try not to think about it Waiting for some big pharma to buy it
Feb 1, 9:35 AM
• !Report Abuse
Add a reply...

140 characters

LEIGHDIST
has anyone heard if DCTH was approved
10/15/12
Reply (4)

• !Report Abuse
View all 4 replies
JMattius: Well at least you are not in the red. I haven't followed that company too much but best of luck if you stay long. I'm sure it will rebound
10/15/12
• !Report Abuse
LEIGHDIST: i don't hold much only 500 so i will stay long and buy more on the drop
10/15/12
• !Report Abuse
Add a reply...

140 characters

Adam Gefvert
DCTH almost crossed the 100dma at 1.89 off the analyst upgrade. I'm long.
9/19/12
Reply (10)

• !Report Abuse
View all 10 replies
sundate36: Hi Adam, do you follow or have an opinion on DNDN by any chance? It looks like it wants to go up ...
10/12/12
• !Report Abuse
Adam Gefvert: I look at DND once in awhile. Don't have an opinion. I like to see a fundamental reason for a stock to go a direction before I trade it.
10/15/12
• !Report Abuse
Add a reply...

140 characters

pablo63
DCTH UP ! for third consecutive day !
8/13/12
Reply (1)

• !Report Abuse
View all 1 replies
pablo63: Must break 2.10.
8/13/12
• !Report Abuse
Add a reply...

140 characters

Chemistfrog
$DCTH trading near its all-time low despite earnings and company update on August 7th and NDA re-filing in August.
8/4/12
Reply (1)

• !Report Abuse
View all 1 replies
nsahbti: Company updates usually keep stocks level until the news is out. you know, making sure there are no surprises. Just buy more if you think.
8/6/12
• !Report Abuse
Add a reply...

140 characters

nsahbti
Is DCTH is up for NDA filing in mid August? Thinking of where to put my HZNP and AMRN wins
8/3/12
Reply (1)

• !Report Abuse
View all 1 replies
ajbrzoz: DCTH NDA filing is expected mid-August: http://bit.ly/OG6kFK
8/3/12
• !Report Abuse
Add a reply...

140 characters

pablo63
DCTH moving stop again ! 1.98 !
7/6/12
Reply (1)

• !Report Abuse
View all 1 replies
Boatyzaffa: It's like butta
7/6/12
• !Report Abuse
Add a reply...

140 characters

pablo63
DCTH < moving stop 1.93>
7/6/12
Reply (1)

• !Report Abuse
View all 1 replies
Boatyzaffa: DCTH- Nice pablo... liked your long MMR trade a couple of hours ago too!
7/6/12
• !Report Abuse
Add a reply...

140 characters

Winning Will
Great spot to enter DCTH for a short term hold. just bought a few thousand shares at $2.02.. short term price target around $2.20
5/17/12
Reply (2)

• !Report Abuse
View all 2 replies
Winning Will: there it goes!
5/21/12
• !Report Abuse
Winning Will: and there's my 2.20 price target.
5/21/12
• !Report Abuse
Add a reply...

140 characters

emburns
Bought 2000 of DCTH @ 3.03
12/27/11
Reply (4)

• !Report Abuse
View all 4 replies
emburns: Just a quick scalp..made 40 bucks.. should have held longer though.
12/27/11
• !Report Abuse
emburns: Should have held out longer.
1/2/12
• !Report Abuse
Add a reply...

140 characters

Chemistfrog
Loving oversold biotechs that haven't "caught back up" yet: CRMD, CTSO.OB, PPHM, BIOD, DCTH, CLSN, CRIS, LPTN and EXEL.
12/3/11
Reply (3)

• !Report Abuse
View all 3 replies
Chemistfrog: CC is Tues, I bought in case they have good news about licensing or resuming their program I'll sell on spike. If no news at CC dump it..
12/5/11
• !Report Abuse
Sakoku: nice spike
12/7/11
• !Report Abuse
Add a reply...

140 characters

DCTH Delcath Systems, Inc.

DCTH

Delcath Systems, Inc.